PHENYLBUTAZONE - phenylbutazone injection Aspen Veterinary Resources, Ltd.


Phenylbutazone 20% Injection 200 mg/mL

KEEP OUT OF REACH OF CHILDREN

FOR HORSES ONLY

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Phenylbutazone 20% Injection (phenylbutazone) is a synthetic, nonhormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound's anti-inflammatory properties. Chemically, phenylbutazone is 4-butyl-1,2-diphenyl-3,5-pyrazolidinedione. It is a pyrazolon derivative entirely unrelated to the steroid hormones, and has the following structural formula:



BACKGROUND PHARMACOLOGY

Kuzell, ^{1, 2, 3} Payne, ⁴ Fleming, ⁵ and Denko ⁶ demonstrated clinical effectiveness of phenylbutazone in acute rheumatism, gout, gouty arthritis and various other rheumatoid disorders in man. Anti-rheumatic and anti-inflammatory activity has been well established by Fabre, ⁷ Domenjoz, ⁸ Wilhelmi, ⁹ and Yourish. ¹⁰ Lieberman ¹¹ reported on the effective use of phenylbutazone in the treatment of painful conditions of the musculosketal system in dogs; including posterior paralysis associated with intervertebral disc syndrome, painful fractures, arthritis, and painful injuries to the limbs and joints. Joshua ¹² observed objective improvement without toxicity following long-term therapy of two aged arthritic dogs. Ogilvie and Sutter ¹³ reported rapid response to phenylbutazone therapy in a review of 19 clinical cases including posterior paralysis, posterior weakness, arthritis, rheumatism, and other conditions associated with lameness and musculoskeletal weakness.

Camberos¹⁴ reported favorable results with phenylbutazone following intermittent treatment of Thoroughbred horses for arthritis and chronic arthrosis (e.g., osteoarthritis of medial and distal bones of the hock, arthritis of stifle and hip, arthrosis of the spine, chronic hip pains, achronic pain in the trapezius muscles, and generalized arthritis). Results were less favorable in cases of traumatism, muscle rupture, strains and inflammations of the third phalanx. Sutter¹⁵ reported favorable response in chronic equine arthritis, fair results in a severely bruised mare, and poor results in two cases where the condition was limited to the third phalanx

INDICATIONS

For relief of inflammatory conditions associated with the musculoskeletal system in horses.

CONTRAINDICATIONS

Treated animals should not be slaughtered for food purposes. Parenteral injections should be made intravenously only; do not inject subcutaneously or intramuscularly. Use with caution in patients who

have a history of drug allergy.

PRECAUTIONS

Stop medication at the first sign of gastrointestinal upset, jaundice, or blood dyscrasia. Authenticated cases of agranulocytosis associated with the drug have occurred in man. To guard against this possibility, conduct routine blood counts at weekly intervals of two weeks thereafter. Any significant fall in th total white count, relative decrease in granulocytes, or black or tarry stools, should be regarded as a signal for immediate cessation of therapy and institution of appropriate counter measures. In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy is required.

Store in refrigerator between 2° - 8°C (36° - 46°F)

DOSAGE AND ADMINISTRATION

HORSES

INTRAVENOUSLY: 1 to 2 g per 1,000 lbs of body weight (5 to 10 mL/1,000 lbs) daily. Injection should be given slowly and with care. Limit intravenous administration to a maximum of 5 successive days, which may be followed by oral phenylbutazone dosage forms.

GUIDELINES TO SUCCESSFUL THERAPY

- 1. Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response.
- 2. Response to phenylbutazone therapy is prompt, usually occurring within 24 hours. If no significant clinical response is evident after 5 days, reevaluate diagnosis and therapeutic approach.
- 3. In animals, phenylbutazone is largely metabolized in 8 hours. It is recommended that a third of the daily dose be administered at 8 hour intervals. Reduce dosage as symptoms regress. In some cases, treatment may be given only when symptoms appear with no need for continuous medication. If long-term therapy is planned, oral administration is suggested.
- 4. Many chronic conditions will respond to phenylbutazone therapy, but discontinuance of treatment may result in recurrence of symptoms.

HOW SUPPLIED

INJECTABLE: **For Horses only: 100 mL vials, 200 mg/mL (1 g/5 mL)** Each mL contians 200 mg of phenylbutazone, 10.45 mg of benzyl alcohol as preservative, sodium hydroxide to adjust pH to 9.5 to 10.0, and water for injection, Q.S.

- 1. Kuzell, W.C., Schaffarzick, R.W., Naugler, W.G., and Mankle, E.A.: AMA Arch. Int. Med. 92:646, 1953.
- 2. Kuzell, W.C., Schaffarzick, R.W., Brown, B. and Mankle, E.A.: Jour. Amer. Med. Assoc. 149:729, 1952.
- 3. Kuzell, W.C., Schaffarzick, R.W., Calif. Med. 777:319, 1952.
- 4. Payne, R.W., Shetlar, M.R., Farr, C., Hellbaum, A.A., and Ishmael, W.K.T.: J.Lab. Clin. Med. 45:331, 1955.
- 5. Fleming, J. and @Will, G.: Ann Rheumat. Dis. 12:95, 1953.
- 6. Denko, C.W., and Rumi, D.: Amer. Practit. 6:1865, 1955.
- 7. Fabre, J. and Berger, A.: Semaine Hop. (Paris) 31:87, 1955.
- 8. Domenjoz, R., Theobald, W. and Morsdorf, K., Arzneimittel-Forsch. 5:488, 1955.
- 9 Wilhelmi, G., and Pulver, R.: Arzneimittel-Forsch. 5:221, 1955.
- 10. Yoursh, N., Paton, B., Brodie, B.B and Burns, J.J.: AMA Arch. Ophth. 53:264, 1955.
- 11. Lieberman, L.L.: Jour. Amer. Vet. Med. Assoc. 125:128, 1954.

- 12. Joshua, J.O.: Vet. Rec. 68:60 (Jan 21), 1956.
- 13. Ogilvie, F.B. and Sutter, M.D.: Vet. Med 52:492-494, 1957.
- 14. Camberos, H.R.: Rev. Med. Vet. (Buenos Aires); 38:9, 1956.
- 15. Sutter, M.F.: Vet Med. 53:83 (Feb.), 1958.


INDICATIONS: For relief of inflammatory conditions associated with the musculoskeletal system in horses.

Intravenous dosage (not for subcutaneous or intramuscular use):

Horses: 1 to 2 g per 1,000 lb body weight (5 to 10 mL/1,000 lb) daily.

Not for use in Horses intended for food.

See package outsert for additional information.



- REFERENCES:

 I. Kuzell, W.C., Schaffarzick, R.W., Naugler, W.G., and Mankle, E.A.: AMA Arch, Int. Med. 92:846, 1963.

 2. Kuzell, W.C., Schaffarzick, R.W., Brown, B. and Mankle, E.A.:
- Jour. Amer. Med. Assoc. 149:729, 1952. 3. Kuzell, W.C., Schaffarzick, R.W., Calif. Med. 77:319, 1952.
- Kurall, W.C., Schaffarziok, R.W., Calif. Mod. 77:319, 1992.
 Payne, R.W., Shetlay, M.R., Farr, C., Hellbaum, A.A. and Ishmani, W.K.T.-J. Lab. Clin. Med. 48:331, 1985.
 Fleming, J. and Will, G.: Ann Rheumat. Dis. 12:95, 1953.
 Denko, C.W., and Rumi, D.: Amer. Practic 6:1895, 1995.
 Fabre, J. and Berger, A. Semaine Hop. Rarisl 31:37, 1995.
 Domenior, R. Thoebald, W. and Morsdorf, K.; Arzneimittel Forsath, 5:438, 1995.
 AdMichael. A. D. Americant Sci. 1995.

- Wilhelmi, G., and Pulver, R.: Arzneimittel-Forsch. 5:221, 1955.
 Yourish, N., Paton, B., Brodie, B.B. and Burns, J.J.: AMA
- Arch. Ophth. 53:264, 1955.
- Arch. Ophth. 3s284, 1955. 11. Libberman, LL. Jour. Arnet. Vet. Med. Assoc. 125:128, 1954. 12. Joshua, J.O.: Vet. Rec. 68:90 (Jan. 21), 1956. 13. Ogivie, F.B. and Sutter, M.D.: Vet. Med. 52:492-494, 1957. 14. Camburors, H.R. Rw. Mod. Vet. Bluenos Airsex; 38:9, 1956. 15. Sutter, M.D.: Vet. Med. 53:83 (Feb.), 1958.

7

INDICATIONS: For relief of inflammatory con-ditions associated with the musculoskeletal system

Intravenous dosage (not for subcutaneous or intramuscular use):

Horses: 1 to 2 g per 1,000 lb body weight (5 to 10 mL/1,000 lb) daily.

Not for use in Horses intended for food. See package outsert for additional information.

Manufactured by: Lenexa, KS 66215, USA

Manufactured for: Aspen Veterinary Resources,® Ltd. Liberty, MO 64068

P-4825-04 Rev. 06-10

Printed in U.S.A. Mfd. in U.S.A.

PHENYLBUTAZONE 20% INJECTION (PHENYLBUTAZONE)

For Horse Doral law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Phenylbutazone 20%. Injection (phenylbutazone) is a synthetic, nonhermonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound's anti-inflammatory properties. Chemically, phenylbutazone is 4-butyl-1,2-diphenyl-3-byvazolidinedione. It is a pyrazolon derivative entirely unrelated to the steroid hormones, and has

BACKGROUND PHARMACOLOGY: Kuzell, 1,2,3 Payne, ⁴ Fleming, ⁵ and Denko ⁶ demonstrated clinical effectiveness of phenylbutazone in acute rheumatism, gout, gouty arthritis, and various other rheumatoid disorders in man. Anti-rheumatic other rheumatoid disorders in man. Anti-rheumatic and anti-inflammatory activity has been well established by Fabre, Openenios, Wilhelmin and Yourish. 10 Lieberman 11 reported on the effective use of phenylbutazone in the treatment of psinful conditions of the musculoskeletal system in dogs; including posterior paralysis associated with intervariabral disc syndrome, painful fractures, arthritis, and painful injuries to the limbs and joints. Joshual 2 observed objective improvement without receipt following logical results are some control of the programma of th Joshua - observed objective improvement without toxicity following long-term therapy of two aged arthritic dogs. Oglivile and Sutter 2 reported rapid response to phenylloutacons therapy in a review of 19 clinical cases including posterior paralysis, posterior weakness, arthritis, rheumatism, and other conditions associated with lameness and musculphederal weakness. musculoskeletal weakness. Camberos¹⁴ reported favorable results with

phenylbutazone following intermittent treatment of Thoroughbred horses for arthritis and chronic arthrosis (e.g., osteoarthritis of medial and distal bones of the hock, arthritis of stifle and hip, bones of the hock, arthritis of stiffe and hip, arthrosis of the spine, chronic hip pains, chronic pain in trapezius muscles, and generalized arthritisl. Results were less favorable in cases of traumatism, muscle rupture, strains and inflammations of the third phalanx. Sutter 15 reported favorable response in chronic equine arthritis, fair results in a severely bruised mare, and poor results in two cases where the condition was limited to the third phalanx.

NINDCATIONS: For railed of inflammatory conditions.

INDICATIONS: For relief of inflammatory conditions associated with the musculoskeletal system in

CONTRAINDICATIONS: Treated animals should not contraindications: reated animals should not be slaughtered for food purposes. Parenteral injections should be made intravenously only; do not inject subcutaneously or intramuscularly. Use with caution in patients who have a history of drug allergy.

PRECAUTIONS: Stop medication at the first sign of gastrointestinal upset, jaundice, or blood dyscrasia. Authenticated cases of agranulocytosis associated with the drug have occurred in man. To guard with the drug have occurred in man. To guard against this possibility, conduct routine blood counts at weekly intervals during the early phase of therapy and at intervals of two weeks thereafter. Any significant fall in the total white count, relative decrease in granulocytes, or black or tarry stools, should be regarded as a signal for immediate cessation of therapy and institution of appropriate counter measures. In the reserved counter measures. In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy is required. Store in a refrigerator between 2°C - 8°C (36°F - 46°F).

DOSAGE AND ADMINISTRATIONS

HORSES INTRAVENOUSLY: 1 to 2 g per 1,000 lbs of body weight [5 to 10 mL/1,000 lbs] daily. Injection should be given slowly and with care. Limit intravenous administration to a maximum of 5 successive days, which may be followed by oral phenylbutazone dosage forms.

- dosage forms.

 GUIDELINES TO SUCCESSFUL THERAPY

 1. Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response.

 2. Response to phenylbutazone therapy is prompt, usually occurring within 24 hours. If no significant clinical response is evident after 5 days, reevaluate diagnosis and therapeutic approach.

 3. In animals, phenylbutazone is largely metabolized in 8 hours. It is recommended that a hird of the daily dose be administered at 8 hour
- third of the daily dose be administered at 8 hour intervals. Reduce dosage as symptoms regress. In some cases, treatment may be given only when symptoms appear with no need for continuous

5

edication. If long-term therapy is planned, oral

administration is suggested.
4. Many chronic conditions will respond to phenylbutazone therapy, but discontinuance of treatment may result in recurrence of symptoms.

HOW SUPPLIED

HOW SUPPLIED INJECTABLE: For Horses only: 100 mL vials, 200 mg/mL (1 g/5 mL) Each mL contains 200 mg of phenylbutazone, 10.45 mg of benzyl alcohol as preservative, sodium hydroxide to adjust pH to 9.5 to 10.0, and water for injection,Q.S.

PHENYLBUTAZONE

phenylbutazone injection

Product	Information
----------------	-------------

Product Type	PRESCRIPTION ANIMAL DRUG LABEL	Item Code (Source)	NDC:46066- 282
--------------	-----------------------------------	--------------------	-------------------

Route of Administration	INTRAVENOUS	DEA Schedule
-------------------------	-------------	---------------------

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
PHENYLBUTAZONE (PHENYLBUTAZONE)	PHENYLBUTAZONE	200 mg in 1 mL

Packaging

ı	- w			
l	# Item Code	Package Description	Marketing Start Date	Marketing End Date
l	1 NDC:46066-282-04	100 mL in 1 VIAL		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANADA	ANADA200371	07/31/2007	

Labeler - Aspen Veterinary Resources, Ltd. (627265361)

Revised: 4/2014 Aspen Veterinary Resources, Ltd.